{
  "docId": "019de077-4649-72e2-aa45-017392de211d",
  "docSlug": "8a7a8508ae9537047e1aabcda9819db4",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 27 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 27,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-4649-72e2-aa45-017392de211d/22",
  "deckHref": "/decks/019de077-4649-72e2-aa45-017392de211d",
  "deckJsonHref": "/decks/019de077-4649-72e2-aa45-017392de211d.json",
  "deckAnchorHref": "/decks/019de077-4649-72e2-aa45-017392de211d#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "1 Management estimate 2 Projected increase in amyotrophic lateral sclerosis from 2015 to 2040, Nature Communications, 2016",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efdeaa1d-0e33-442c-bbc3-462fc731fd02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.52,
        "y": 0.55
      },
      "kind": "metric",
      "text": "~24% Growth in patients by 2040 in the US and EU",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25988cfa-98a8-4c25-a650-d4c0549a3e3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.13,
        "y": 0.55
      },
      "kind": "metric",
      "text": "ALS drug (Relyvrio) was priced at $158,000/year",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f541a9f-48fc-4941-ae1c-ff87ea293a5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "metric",
      "text": "~$3B Annual Market Opportunity",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f6e2b42-be07-487b-9fd7-650e3541fa3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.13,
        "y": 0.25
      },
      "kind": "metric",
      "text": ">80,000 ALS patients in NeuroSense’s planned target market",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dcce078b-def7-41e1-9247-0ec857cdf0af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "PrimeC has Strong Commercial Potential in ALS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f9ddc07-8a98-4259-81c2-907210999ad0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 22,
      "from": 22,
      "beatId": "6d16c563-7507-43cd-a39e-fb648e52209f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Market Sizing",
      "beatSlug": null,
      "evidence": "The deck highlights the commercial potential of PrimeC in the ALS market",
      "position": 3,
      "confidence": 0.9,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}